Comparative Pharmacology
Head-to-head clinical analysis: CENOBAMATE versus PRIMIDONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CENOBAMATE versus PRIMIDONE.
CENOBAMATE vs PRIMIDONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cenobamate is a tetrazole-derived anticonvulsant that modulates GABA A receptors, preferentially inhibiting the persistent sodium current and activating potassium currents (M-current). It also enhances GABA-mediated inhibition and reduces excitatory neurotransmitter release.
Primidone is a barbiturate that enhances GABA-A receptor activity, increasing chloride ion conductance and neuronal inhibition. It also has active metabolites, phenobarbital and phenylethylmalonamide, which contribute to anticonvulsant effects.
Cenobamate 200 mg orally once daily initially, titrated weekly by 50 mg to a target dose of 400 mg once daily; maximum 400 mg/day.
Initial: 100-125 mg orally at bedtime for 3 days; increase to 100-125 mg twice daily for 3 days, then 100-125 mg three times daily for 3 days; maintenance: 250 mg three times daily. Maximum: 500 mg four times daily.
None Documented
None Documented
Clinical Note
moderatePrimidone + Digoxin
"The metabolism of Digoxin can be increased when combined with Primidone."
Clinical Note
moderatePrimidone + Digitoxin
"The metabolism of Digitoxin can be increased when combined with Primidone."
Clinical Note
moderatePrimidone + Torasemide
"The metabolism of Torasemide can be increased when combined with Primidone."
Clinical Note
moderatePrimidone + Etacrynic acid
"Primidone may increase the hypotensive activities of Etacrynic acid."
The terminal elimination half-life is approximately 10-17 hours in adults. Steady-state is achieved within 2-3 days. In patients with moderate to severe hepatic impairment, half-life may be prolonged.
Primidone: 10-12 hours; phenobarbital metabolite: 48-120 hours; PEMA: 16-18 hours. Steady-state requires 4-7 days for primidone but up to 2-3 weeks for phenobarbital accumulation.
Renal excretion accounts for approximately 92% of the administered dose, with 62% as unchanged drug and 30% as metabolites. Fecal excretion is minimal (<2%).
Renal: approximately 40% unchanged, 30% as phenobarbital, 20% as phenylethylmalonamide (PEMA); fecal: <5%
Category C
Category D/X
Anticonvulsant
Anticonvulsant